UCB, Amgen’s Evenity under review in Europe
The European Medicines Agency has accepted UCB and Amgen’s submission seeking approval for use of bone-boosting drug Evenity in post-menopausal women and in men at increased risk of fracture.
Read More
Tag: fractures
- Venner Shipley announces opening of new Bristol office
- AAX Biotech and Vascurie announce new neuro-oncology collaboration
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
- Ipsen announces new data on Dysport in neurological disease
